Investical Earnings & investing calendar Earnings & investing calendar
/
SSumitomo Pharma Co.,Ltd. logo
4506TSE Prime

Sumitomo Pharma Co.,Ltd.

住友ファーマ Yahoo Finance

Recent & upcoming events

Oct 30
Earnings 2:00 approx.
Q2 earnings announcement (scheduled)
Add to Google Calendar
Sep 28
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Sep 27
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Jul 31
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 24
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
May 13
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Oct 30
Earnings 2:00 approx.
Q2 earnings announcement (scheduled)
Add to Google Calendar
2027
Jan 29
Earnings 1:00 approx.
Q3 earnings announcement (scheduled)
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Apr 30
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar
Jul 30
Est.
Earnings 2:00 approx.
Q1 earnings
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 29
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar

KPI highlights

FY26
Revenue ¥453.29B YoY +13.7%
Operating income ¥107.34B margin 23.7%
Net income ¥106.86B YoY +352.2%
EPS ¥269 YoY +352.2%
P/E —
ROE 46.3% Equity ratio 36% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥540.00B +19.1%
Operating income ¥90.00B -16.2%
Net income ¥77.00B -27.9%
EPS ¥173 -35.7%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥75.69B¥76.96B¥82.39B¥79.53B——
Operating income ¥-51.57B¥-34.93B¥-31.25B¥-237.11B——
Net income ¥-38.86B¥-28.87B¥-49.96B¥-197.23B——
Operating CF ¥-71.97B¥-61.73B¥-37.79B¥-185.75B——

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 52.9%国内機関 12%未開示 32.2%202120222023202420252026
事業法人国内機関海外機関個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

住友化学株式会社 51.8%住友化学株式会社日本マスタートラスト信託銀行株式会社 6.3%日本マスタートラスト信託銀行株式会社（信託口）株式会社SMBC信託銀行（株式会社三 1.8%株式会社SMBC信託銀行（株式会社三井住友銀行退職給付信託口）202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
住友化学株式会社 205,634,000 51.8% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社（信託口） 25,038,000 6.3% Yuho (EDINET)
株式会社SMBC信託銀行 7,000,000 1.8% Yuho (EDINET)
株式会社日本カストディ銀行（信託口） 6,219,000 1.6% Yuho (EDINET)
住友生命保険相互会社 5,776,000 1.5% Yuho (EDINET)
BNYM AS AGT/CLTS 10 PERCENT 4,573,000 1.2% Yuho (EDINET)
稲畑産業株式会社 4,400,000 1.1% Yuho (EDINET)
THE BANK OF NEW YORK, TREATY JASDEC ACCOUNT 3,977,000 1.0% Yuho (EDINET)
日本生命保険相互会社 3,790,000 1.0% Yuho (EDINET)
J.P. MORGAN BANK LUXEMBOURG S.A. 381593 3,030,000 0.8% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

6/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 13.3%
✓ Positive operating cash flow ¥71.72B
✓ ROA improved YoY 3.2% → 13.3%
✗ Operating CF exceeds net income (accrual quality) OCF ¥71.72B / net income ¥106.86B
✓ Equity ratio improved* Substitute for the original “decrease in long-term debt” 22.8% → 36.4%
✗ Current ratio improved 1.05× → 1.03×
✓ No dilution (shares outstanding did not increase) 397,900,000 → 397,900,000
✗ Gross margin improved 61.5% → 56.7%
✓ Asset turnover improved 0.54× → 0.56×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 36.4%
Current ratio 1.0×
Years of positive operating CF 9 of last 10 yrs
Payout ratio —
Latest fiscal year result Profit (net income ¥106.86B)

Performance history

Last 10 years
0億円1,400億円2,800億円4,200億円5,600億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 4,1164,7804,5934,8275,1605,6005,5553,1463,9884,533
Operating income 528—579832712602-770-3,5492881,073
Ordinary income 543609————————
Net income 290375486408562564-745-3,1502361,069
Total assets 7,9408,0148,34712,52913,08113,08011,3479,0757,4268,046
Equity 4,6074,8314,9815,2955,8066,0794,0671,5611,6952,925

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥73¥94¥122¥103¥142¥142¥-188¥-793¥59¥269
ROE 6.4%8.0%10.2%7.9%10.1%9.5%-14.7%-111.9%14.5%46.3%
Operating CF 2169634874611,356312119-2,419165717
Investing CF -597-205-350-3,12788.8-183524330998225
Financing CF 98.8-285-2862,311-572-214-1,468779-1,088-913
FCF -381758137-2,6661,445130644-2,0891,163943

Source: EDINET (Annual Securities Report) (fetched 2026-09-25) *Some metrics supplemented from additional sources

Key financial metrics

High ROE ✓

Sector positioning

Relative standing within the sector

IR disclosure history

Timely disclosures & annual reports
Is this information incorrect?

Data provided by Twelve Data